Image Credit: alen85/123rf.com
A recent clinical trial has shown promising results for a new wireless retinal implant designed to restore vision in patients suffering from geographic atrophy, a severe form of age-related macular degeneration (AMD). This condition affects over five million individuals globally and typically leads to significant central vision loss, impacting daily activities such as reading and recognizing faces.
The international study, known as the PRIMAvera trial, involved 38 patients aged 60 and older from 17 medical centers located in France, Germany, Italy, the Netherlands, and the United Kingdom. Results indicated that 81 percent of participants experienced meaningful restoration of central vision after receiving the implant. Additionally, 84 percent reported the ability to read numbers or words at home within one year of the procedure, with some even able to read entire pages from a book.
The implant, which is approximately 2mm in size, functions by replacing damaged photoreceptors in the retina. It operates in conjunction with a pair of specialized glasses equipped with a camera that captures images. These images are transmitted via near-infrared light to the implant, which then converts the signals into electrical pulses that stimulate the surviving cells in the retina. Users have the ability to adjust zoom and contrast settings to suit various visual tasks.
Conducted as the largest clinical trial of a photovoltaic retinal prosthesis to date, the PRIMAvera results are significant, especially given that geographic atrophy is a leading cause of irreversible blindness in older adults. Currently, there are no approved treatments that can restore vision once it is lost due to this condition, making these findings particularly noteworthy.
All procedure-related side effects reported during the trial had resolved by the 12-month follow-up, underscoring the safety profile of the implant in addition to its efficacy. Following these encouraging results, Science Corporation, the developer of the PRIMA system, has submitted applications for regulatory approval in both Europe and the United States. The first U.S. implantation of the device was performed by the University of Pittsburgh Medical Center in 2020.
The implications of this technology could be profound for those affected by geographic atrophy, as it represents a potential breakthrough in the treatment of a condition that currently has no means of reversing vision loss.
Check out the original article here: Source link
